Overexpression of serglycin (SRGN) in human breast can- cer suggested a poor prognosis. However, its role in triple- negative breast cancer (TNBC) recurrence and metastasis remains unclear. 1–3 To explore the clinical value of SRGN, we used 144 breast cancer samples to determine SRGN expression(Figures1Aand1C).TheSRGNexpressionlevel was closely associated with the overall survival of breast cancer (Figure 1B; Figure S1A). Additionally, immuno- histochemistry (IHC) staining showed that serglycin was expressed in the tumor stroma (Figure 1F). EGFR and Ki67, which were significantly correlated with worse sur- vival and a poor prognosis in TNBC patients, showed higher expression levels in TNBC tissue. 4 The luminal subtype expressed GATA3, which regulates differentiation and suppresses dissemination in breast cancer. 5 We found that SRGN was positively correlated with EGFR and Ki67. Additionally, we found that the SRGN mRNA level was negatively correlated with GATA3 (Figures1G, 1L, and 1M; Figures S1B-S1D).
展开▼
